Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

Contributed by: Business Wire

Logo

Tags

FDA

Data Management

Technology

Oncology

Professional Services

Artificial Intelligence

Clinical Trials

Cardiology

Science

Biotechnology

Software

Data Analytics

Other Science

Health

Research

Cancer

More Like This

Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

K Navigator home screen.

Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

PR Newswire associated0

Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment